
Translational Neuroimmunology in Multiple Sclerosis
From Disease Mechanisms to Clinical Applications
Description
Key Features
- Provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis and the translation of this research to immunotherapy treatment
- Edited by renowned leaders in the field of neuroimmunology and multiple sclerosis
- Contains the latest resource material for basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology
- 2017 BMA Medical Book Awards Highly Commended in Neurology
Readership
Basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology
Table of Contents
Section I: MS Pathology and Mechanisms
1. MS Pathology: Inflammation versus Neurodegeneration
2. Immune Dysregulation in Multiple Sclerosis
3. CNS immune regulation
4. Genetics of Multiple Sclerosis
5. MS Subtypes: How the Natural History of MS was Challenged Due to Treatment
6. Pediatric-Onset MS as a Window into Early Disease Targets and Mechanisms
7. Sex-related factors in multiple sclerosisSection II: Other Patho-Mechanisms
8. Environmental Factors and their regulation of immunity in MS
9. Gut Microbiota in Multiple Sclerosis: A Bioreactor driving Brain Autoimmunity
10. Neuroendocrine Checkpoints of Innate Immune Responses in Multiple Sclerosis: Reciprocal Interactions Between Body and Brain
11. Fighting chronic neuroinflammation by boosting autoimmunity: the distinction between neurodegenerative diseases and multiple sclerosis
12. Neuroactive steroids and NeuroinflammationSection III: Surrogate Markers in Multiple Sclerosis
13. Surrogate Markers in Multiple Sclerosis: The Role of MRISection IV: Currently Approved Therapies – Injectable
14. Interferon β in Multiple Sclerosis: A Review
15. Glatiramer Acetate - From Bench to Bed and Back
16. Natalizumab
17. Alemtuzumab (Campath-1H)
18. Currently approved DMDs-injectable: cytotoxic immunosuppressive drugsSection V: Currently Approved DMDs – Oral
19. Fingolimod (Gilenya)
20. Oral Dimethyl Fumarate (BG-12; Tecfidera®) for Multiple Sclerosis
21. Emerging Therapies for Multiple SclerosisSection VI: Symptomatic and Complementary Treatments
22. Treatment of acute relapses in Multiple sclerosis
23. Shedding light on Vitamin D and MS
24. Symptomatic and Complementary Treatments
25. Cognitive Impairment in Multiple SclerosisSection VII: Novel and Emerging Strategies
26. Personalized Medicine and Theranostics: Applications to Multiple Sclerosis
27. Stem cell based-therapies, remyelination and repair promotion, in the treatment of multiple sclerosis
28. Stem cells in Multiple Sclerosis
29. T cell vaccination: An insight into T cell regulation
30. Reversal of Misfortune: Therapeutic Strategies on the Horizon
Product details
- No. of pages: 502
- Language: English
- Copyright: © Academic Press 2016
- Published: May 10, 2016
- Imprint: Academic Press
- Hardcover ISBN: 9780128019146
- eBook ISBN: 9780128020074
About the Editors
Ruth Arnon

Affiliations and Expertise
Ariel Miller

Prof. Miller is the founder and first president of the Israel Society for Neuroimmunology (President 2000-2009), elected member of the American Neurological Association (ANA) (2005), and the recipient of the Hershel Rich Technion Innovation Award - 2006, for his contribution in the field of Pharmacogenetics and 'Personalized Medicine'.
Prof. Miller's scientific and medical work is dedicated to elucidation of the mechanisms underlying Brain diseases, with special focus on implementation of therapeutic strategies for Multiple Sclerosis as well as Pharmacogenetics towards development of 'Personalized Medicine'.
Affiliations and Expertise
Ratings and Reviews
There are currently no reviews for "Translational Neuroimmunology in Multiple Sclerosis"